Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of Zoom meeting, Skype calls, and deadlines has predictably returned. But what can you do? The world keeps spinning, despite the dizzying events occurring outside your door. To cope, yes, we are firing up the coffee kettle and brewing cups of stimulation. Our choice today is the seasonal pumpkin spice. Feel free to join us. Meanwhile, here are a few tidbits to help you get started. We hope your day is smashing, and do keep in touch. …

The share of Americans who say they are likely to get a Covid-19 vaccine as soon as it’s available is dropping — and the decline is notably more pronounced among Black Americans than among white individuals, according to a new survey from STAT and The Harris Poll. The survey found that 59% of white Americans indicated they would get vaccinated as soon as a vaccine is ready, a decline from 70% in mid-August. Only 43% of Black individuals said they would pursue a vaccine as soon as it was available, a sharp drop from 65% in mid-August.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one observe that the Catalyst effort to file a patent infringement against Jacobus has a novel twist? It appears that Jacobus has been working in their drug for a good number of years, but is now in litigation over infringing on a patent granted less than THREE WEEKS AGO?
    There will be more to follow, but this is indeed novel to this deponent.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy